{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T18:52:35Z","timestamp":1725821555040},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s11914-008-0004-x","type":"journal-article","created":{"date-parts":[[2008,3,28]],"date-time":"2008-03-28T17:08:02Z","timestamp":1206724082000},"page":"17-23","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous zoledronic acid for the treatment of osteoporosis"],"prefix":"10.1007","volume":"6","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,29]]},"reference":[{"key":"4_CR1","unstructured":"National Osteoporosis Foundation: Fast Facts on Osteoporosis. http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm . Accessed July 27, 2007."},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bone.2005.11.024","volume":"38","author":"J.Y. Reginster","year":"2006","unstructured":"Reginster JY, Burlet N: Osteoporosis: a still increasing prevalence. Bone 2006, 38:S4\u2013S9.","journal-title":"Bone"},{"key":"4_CR3","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785\u2013795.","DOI":"10.1001\/jama.285.6.785"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"J.A. Kanis","year":"2001","unstructured":"Kanis JA, Johnell O, Oden A, et al.: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989\u2013995.","journal-title":"Osteoporos Int"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/1529-0131(199907)42:7<1378::AID-ANR11>3.0.CO;2-I","volume":"42","author":"N.K. Arden","year":"1999","unstructured":"Arden NK, Nevitt MC, Lane NE, et al.: Study of Osteoporotic Fractures Research Group. Osteoarthritis and risk of falls, rates of bone loss, and osteoporotic fractures. Arthritis Rheum 1999, 42:1378\u20131385.","journal-title":"Arthritis Rheum"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R. Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, et al.: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 2007, 22:465\u2013475.","journal-title":"J Bone Miner Res"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1359\/jbmr.060301","volume":"21","author":"S.K. Brenneman","year":"2006","unstructured":"Brenneman SK, Barrett-Connor E, Sajjan S, et al.: Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006, 21:809\u2013816.","journal-title":"J Bone Miner Res"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","volume":"16","author":"J.A. Kanis","year":"2005","unstructured":"Kanis JA, Johnell OA: Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005, 16:229\u2013238.","journal-title":"Osteoporos Int"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s001980200033","volume":"13","author":"S.E. Gabriel","year":"2002","unstructured":"Gabriel SE, Tosteson AN, Leibson CL, et al.: Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002, 13:323\u2013330.","journal-title":"Osteoporos Int"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00198-006-0310-z","volume":"18","author":"S.H. Gehlbach","year":"2007","unstructured":"Gehlbach SH, Avrunin JS, Puleo E, Spaetyh R: Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 2007, 18:805\u2013810.","journal-title":"Osteoporos Int"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-006-0206-y","volume":"18","author":"B. Haussler","year":"2007","unstructured":"Haussler B, Gothe H, Gold D, et al.: Epidemiology, treatment and costs of osteoporosis in Germany\u2014the BoneEVA Study. Osteoporos Int 2007, 18:77\u201384.","journal-title":"Osteoporos Int"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00198-004-1680-8","volume":"16","author":"P. Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005, 16:134\u2013141.","journal-title":"Osteoporos Int"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2214\/ajr.182.2.1820297","volume":"182","author":"N. Kim","year":"2004","unstructured":"Kim N, Rowe BH, Raymond G, et al.: Underreporting of vertebral fractures on routine chest radiography. AJR Am J Roentgenol 2004, 182:297\u2013300.","journal-title":"AJR Am J Roentgenol"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1497.2006.00395.x","volume":"21","author":"C.A. Morris","year":"2006","unstructured":"Morris CA, Carrino JA, Lang P, et al.: Incidental vertebral fractures on chest radiographs. Recognition, documentation, and treatment. J Gen Intern Med 2006, 21:352\u2013356.","journal-title":"J Gen Intern Med"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archinte.165.8.905","volume":"165","author":"S.R. Majumdar","year":"2005","unstructured":"Majumdar SR, Kim N, Colman I, et al.: Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patents. Arch Intern Med 2005, 165:905\u2013909.","journal-title":"Arch Intern Med"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11914-005-0014-x","volume":"3","author":"E.M. Lewiecki","year":"2005","unstructured":"Lewiecki EM: Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 2005, 3:75\u201383.","journal-title":"Curr Osteoporos Rep"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"D.M. Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al.: for the HORIZON Pivotal Fracture Trial: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809\u20131822.","journal-title":"N Engl J Med"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"D.M. Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, et al.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118\u20134124.","journal-title":"J Clin Endocrinol Metab"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"I.C. Chesnut","year":"2004","unstructured":"Chesnut IC, Skag A, Christiansen C, et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241\u20131249.","journal-title":"J Bone Miner Res"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"S.R. Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077\u20132082.","journal-title":"JAMA"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"S.T. Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344\u20131352.","journal-title":"JAMA"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"M.R. McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333\u2013340.","journal-title":"N Engl J Med"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J. Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83\u201391.","journal-title":"Osteoporos Int"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"J.A. Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453\u20131460.","journal-title":"Curr Med Res Opin"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s00198-006-0085-2","volume":"17","author":"J.C. Lo","year":"2006","unstructured":"Lo JC, Pressman AR, Omar MA, Ettinger B: Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006, 17:922\u2013928.","journal-title":"Osteoporos Int"},{"key":"4_CR26","unstructured":"Weiss TW, von Allmen H, Henderson SC, et al.: Persistency rates across weekly and monthly bisphosphonates: results from the IMS Health Longitudinal Prescription Database [poster P8.13]. Presented at the National Osteoporosis Foundation 7th International Symposium on Osteoporosis: Translating Research into Clinical Practice. Washington, DC; April 18\u201322, 2007."},{"key":"4_CR27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"J.J. Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, et al.: The impact of compliance with osteoporosis therapy on fracture rates in clinical practice. Osteoporos Int 2004, 15:1003\u20131008.","journal-title":"Osteoporos Int"},{"key":"4_CR28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"K.F. Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ: Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006, 38:922\u2013928.","journal-title":"Bone"},{"key":"4_CR29","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"E.S. Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013\u20131022.","journal-title":"Mayo Clin Proc"},{"key":"4_CR30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","volume":"80","author":"R.R. Recker","year":"2005","unstructured":"Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856\u2013861.","journal-title":"Mayo Clin Proc"},{"key":"4_CR31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","volume":"60","author":"A. Cooper","year":"2006","unstructured":"Cooper A, Drake J, Brankin E, the PERSIST Investigators: Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006, 60:896\u2013905.","journal-title":"Int J Clin Pract"},{"key":"4_CR32","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"K. Lyles","year":"2007","unstructured":"Lyles K, Colon-Emeric C, Magaziner J, et al.: Zoledronic acid reduces clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799\u20131809.","journal-title":"N Engl J Med"},{"key":"4_CR33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M. McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, et al.: Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007, 41:122\u2013128.","journal-title":"Bone"},{"key":"4_CR34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","volume":"58","author":"B.J. Gertz","year":"1995","unstructured":"Gertz BJ, Holland SD, Kline WF, et al.: Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995, 58:288\u2013298.","journal-title":"Clin Pharmacol Ther"},{"key":"4_CR35","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"P.C. Groen De","year":"1996","unstructured":"De Groen PC, Lubbe DF, Hirsch LJ, et al.: Esophagitis associated with use of alendronate. N Engl J Med 1996, 335:1016\u20131021.","journal-title":"N Engl J Med"},{"key":"4_CR36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.smj.0000221637.90495.66","volume":"99","author":"T.W. Downey","year":"2006","unstructured":"Downey TW, Foltz SH, Boccuzzi SJ, et al.: Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006, 99:570\u2013575.","journal-title":"South Med J"},{"key":"4_CR37","unstructured":"Aclasta Package Insert. Basel, Switzerland: Novartis Pharmaceuticals; 2007."},{"key":"4_CR38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S. Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479\u20131491.","journal-title":"J Bone Miner Res"},{"key":"4_CR39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"S.B. Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753\u2013756.","journal-title":"Ann Intern Med"},{"key":"4_CR40","first-page":"801","volume":"35","author":"P. Sambrook","year":"2006","unstructured":"Sambrook P, Over I, Goss A, New Zealand Bone and Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia, and the Australian Dental Association: Bisphosphonates and osteonecrosis of the jaw. Clinical practice position. Aust Fam Physician 2006, 35:801\u2013803.","journal-title":"Aust Fam Physician"},{"key":"4_CR41","first-page":"3078","volume":"103","author":"D. Felsenberg","year":"2006","unstructured":"Felsenberg D, Hoffmeister B, Amling M, et al.: Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arztebl 2006, 103:3078\u20133081.","journal-title":"Dtsch Arztebl"},{"key":"4_CR42","unstructured":"National Osteoporosis Foundation: Osteoporosis Clinical Practice Guideline. http:\/\/www.nof.org\/professionals\/clinical.htm . Accessed July 27, 2007."}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-008-0004-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-008-0004-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-008-0004-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:33:43Z","timestamp":1559421223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-008-0004-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s11914-008-0004-x","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}